Only about 1 in 5 employers cover GLP-1 drugs for weight loss. If yours doesn't, you have more options than you probably think — from appealing a denial to manufacturer programs and lower-cost alternatives.
Your doctor says you are a good candidate for Wegovy or Zepbound. You call your insurance company. They say it's not covered, so you are looking at spending from $1,000 to $1,500 a month in order to follow your doctor's advice.
This is a very common experience in 2026, and it's frustrating — especially given how clearly effective these medications are. The good news is that a denial is not always the end of the road. Here's a clear-eyed map of where things stand and what you can actually do about it.
Before anything else, get the denial in writing and read it carefully. Insurance denials for GLP-1s typically fall into a handful of categories, and each one has a different playbook.
Your employer's plan simply excludes weight-loss medications. This is the most common situation — and the hardest to appeal through the insurance company, because there's no clinical decision to overturn. It's a plan design choice. Your options here are to go over the insurer to the employer (more on that below), try the diabetes indication if applicable, or explore alternatives.
This is a bureaucratic hurdle, not necessarily a final no. Most GLP-1 denials at this stage are automated — a claims system flagging missing documentation, not a doctor deciding you don't qualify. This type of denial is very often overturnable on appeal.
Your insurer wants you to try a cheaper medication first before approving the GLP-1. Usually this means demonstrating you've tried (and failed on) something like orlistat, phentermine, or a supervised weight loss program. Ask your prescriber what documentation of prior attempts you already have.
Wegovy and Zepbound are FDA-approved for a BMI of 30 or higher, or 27+ with a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or sleep apnea. If you have a comorbidity and your doctor didn't explicitly document it on the prior authorization form, the claim may be denied purely for missing paperwork. This is one of the most fixable types of denial.
Most initial GLP-1 denials are automated. A real human rarely reviews the first rejection. A well-prepared appeal — specific, documented, and written to match the insurer's own criteria — succeeds up to 80% of the time according to patient advocacy sources.
If your first appeal is denied, you are still entitled to a second-level internal appeal and then an external independent review. External reviews — conducted by a third party with no financial relationship to your insurer — overturn internal decisions surprisingly often for medically appropriate care.
Many prescribers have staff who handle prior authorizations routinely and know what your specific insurer is looking for. Don't assume your doctor's office has already submitted the strongest possible documentation — ask explicitly: "Is there anything else I can provide that would help the appeal?" A peer-to-peer review request, where your doctor calls the insurer's medical director directly, is another option that can be very effective.
If you have type 2 diabetes or prediabetes, your coverage situation is meaningfully different. 55% of employers cover GLP-1 drugs for diabetes, versus around 20% for weight loss. Ozempic and Mounjaro are FDA-approved for type 2 diabetes and are more consistently covered under the diabetes indication.
If your A1C is elevated — even in the prediabetes range — and you have other risk factors, it's worth an honest conversation with your doctor about whether the diabetes or cardiovascular indication is the medically accurate framing for your situation. This isn't gaming the system; it's making sure the full clinical picture is documented accurately.
Most people don't realize that if your employer is self-insured (as most large employers are), your insurer doesn't actually decide what's covered — your employer does. The insurer administers the plan; the employer designed it. The denial may simply reflect a plan design choice your HR or benefits team made, and that choice can be changed.
This is a longer play, but worth pursuing especially if multiple employees are affected. A few approaches:
If coverage isn't coming, there are legitimate alternatives worth knowing about.
Both Novo Nordisk and Eli Lilly offer savings cards for commercially insured patients. These typically cap your monthly out-of-pocket at $25 (Wegovy) or $550 (Zepbound's vial program) for eligible patients. The catch: these programs usually exclude patients on Medicare, Medicaid, or other government insurance. Check the manufacturer's website directly for current terms, as they change frequently.
Eli Lilly launched a direct cash-pay vial program for Zepbound in 2024. The lower starter doses are meaningfully cheaper than retail pharmacy pricing — around $349-$499 per month depending on dose, compared to $1,000+ through standard channels. You order directly from LillyDirect.com with a prescription. No insurance needed.
Medicaid coverage varies by state, with 13 states offering coverage of GLP-1s for weight loss as of early 2026. If your income qualifies, this is worth checking — Medicaid eligibility is broader than many people realize, particularly for adults with qualifying health conditions.
In December 2025, the Centers for Medicare & Medicaid Services announced plans to expand access to GLP-1 medications and may cap copays at $50 per month for eligible Medicare beneficiaries. If you're on Medicare, check for updated coverage under your Part D plan and ask your prescriber about the Bridge prior-authorization pathway.
Companies like Ro, Hims & Hers, Found, and Henry Meds offer GLP-1 prescriptions through telehealth at monthly subscription rates that are often lower than retail pharmacy cash prices. These programs typically include medical supervision, which is important on these medications. Prices and availability change frequently, so compare several options. Make sure you're using a licensed, FDA-regulated pharmacy — not a compounding pharmacy offering "compounded semaglutide," which has been flagged by the FDA for safety issues.
During the 2023-2024 Ozempic and Wegovy shortages, compounded semaglutide and tirzepatide were widely available and much cheaper. The FDA declared both drugs off the shortage list in 2025, which makes large-scale compounding legally restricted. Compounded versions still appear online, but the FDA has received hundreds of adverse event reports tied to them, and counterfeit products with fake labels are a documented problem. The Lilly direct vial program is a legitimate lower-cost alternative; unverified compounding sources are not the same thing.
Coverage for GLP-1 weight-loss drugs is expanding slowly, under real cost pressure, and unevenly distributed — heavily skewed toward larger employers and higher-income workers. A 2026 survey found that two in three employed adults would be more likely to use GLP-1 therapy if employer coverage or behavioral support programs were available, which tells you just how much access barriers are suppressing use of medications that work.
That's not going to change overnight. But the options above are real, available now, and worth working through systematically. A denied claim is often not the final answer — and even when it is, there are paths to access that don't require paying $1,300 a month at a retail pharmacy.